BioCentury
ARTICLE | Company News

AZ, Circassia deal

March 23, 2017 8:52 PM UTC

AstraZeneca agreed to share rights to two chronic obstructive pulmonary disease therapies with Circassia. Circassia will lead promotion of AZ's Tudorza Pressair aclidinium bromide in the U.S., and may opt to acquire full U.S. rights. Circassia will also obtain full U.S. rights to Duaklir Pressair aclidinium bromide/formoterol fumarate.

FDA approved Tudorza in 2012. The pharma said it expects an FDA submission for Duaklir, which is approved in Europe, in 2018. Both products are delivered via the Pressair inhaler, marketed in some countries as Genuair. AZ said the deal will allow it to focus on its other respiratory disease assets, including Symbicort budesonide/formoterol, Bevespi Aerosphere gylcopyrrolate/formoterol fumarate and benralizumab...